ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,127.79
1.26%
Dow Jones
38,675.68
1.18%
US Dollar vs MXN
16.9724
0.00%
Brent Oil
82.765
0.00%
Bitcoin
63,767.58
1.40%
Registration Strip Icon for default Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. ImmunityBio Inc (IBRX)

  7. ImmunityBio Inc (IBRX) Noticias

IBRX ImmunityBio Inc

9.07
0.10 (1.11%)
03 May 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
ImmunityBio Inc IBRX NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
Upgrade Icon
0.10 1.11% 9.07 18:59:42
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
9.48 8.645 10.01 9.15 8.97
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
02/5/202415:04BWImmunityBio, Serum Institute of India Agree on an Exclusive..
30/4/202407:00BWImmunityBio Executive Chairman Dr. Patrick Soon-Shiong to..
24/4/202423:03BWImmunityBio Announces Positive Overall Survival Results of..
22/4/202420:56BWImmunityBio Announces FDA Approval of ANKTIVA®,..
06/3/202408:00BWNIAID-Sponsored Study Shows N-803 Combined with Neutralizing..
05/3/202408:00BWN-803 Combined with Natural Killer Cells Showed Potential to..
26/2/202415:43EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26/2/202415:40EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26/2/202415:38EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/2/202420:28EDGAR2Form 8-K - Current report
21/2/202408:00BWImmunityBio Announces Full Accrual of First Two Phases of..
06/2/202420:14EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/2/202408:00BWImmunityBio Quality-of-Life Study in BCG-Unresponsive..
02/2/202418:38EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/2/202418:33EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/1/202420:59EDGAR2Form SC 13D/A - General statement of acquisition of..
03/1/202420:41EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/1/202420:40EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/1/202405:08EDGAR2Form 8-K - Current report
02/1/202405:00BWImmunityBio Announces $320 Million Investment by Oberland..
16/11/202308:00BWImmunityBio to Participate in 35th Annual Piper Sandler..
08/11/202320:28EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/11/202308:00BWFirst Data for ImmunityBio’s Memory Cytokine-Enriched NK..
26/10/202311:03DJNImmunityBio Shares Rally as FDA Accepts N-803 Resubmission
26/10/202308:00BWFDA Accepts ImmunityBio’s BLA Resubmission as Complete and..
23/10/202310:00DJNImmunityBio Shares 11% Higher on License Application..
23/10/202308:00BWImmunityBio Announces Biological License Application..
28/9/202305:06EDGAR2Form DEF 14C - Other definitive information statements
22/9/202314:06EDGAR2Form D - Notice of Exempt Offering of Securities
21/9/202315:25EDGAR2Form SC 13D/A - General statement of acquisition of..
11/9/202305:25EDGAR2Form 8-K - Current report
11/9/202305:00BWImmunityBio Announces $470 Million Equity and Debt Financing..
06/9/202318:41EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/9/202318:39EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/9/202307:30EDGAR2Form 8-K - Current report
29/8/202304:45PRNUSSHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders..
28/8/202320:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/8/202319:58EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/8/202304:45PRNUSSHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders..
16/8/202304:45PRNUSSHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders..
15/8/202315:15EDGAR2Form 8-K - Current report
11/8/202304:45PRNUSIBRX SHAREHOLDER ALERT: Jakubowitz Law Reminds ImmunityBio..
09/8/202304:45PRNUSSHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders..
08/8/202315:15EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
04/8/202304:45PRNUSIBRX SHAREHOLDER ALERT: Jakubowitz Law Reminds ImmunityBio..
03/8/202308:00BWImmunityBio Names Enrique Diloné as Chief Technology Officer
02/8/202304:45PRNUSSHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders..
28/7/202304:45PRNUSIBRX SHAREHOLDER ALERT: Jakubowitz Law Reminds ImmunityBio..
26/7/202304:45PRNUSSHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders..
25/7/202316:02EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]

Su Consulta Reciente

NASDAQ
IBRX
ImmunityBio
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados